Table 1 Patient and healthy subject characteristics
Blood | Lung | MLN | ||||
|---|---|---|---|---|---|---|
HC (n = 21) | IPF (n = 27) | Control (n = 9) | IPF (n = 11) | Control (n = 13) | IPF (n = 10) | |
Age, years (95% CI) | 56 (52–61) | 70 (67–73) | 50 (56–66) | 59 (55–63) | 59 (56–61) | 58 (53–61) |
Gender: M/F (n, (%)) | 12 (57%) /9 | 19 (70%)/8 | 5 (55%)/4 | 9 (81%)/2 | 8 (62%)/5 | 9 (90%)/1 |
Diagnosis | ||||||
-MDD: IPF/Prob IPF/Pos IPF(n, (%)) | 22 (81%)/5/0 | 11 (100%)/0/0 | 10 (100%)/0/0 | |||
PA obtained (%) | 22 | 100 | 100 | |||
History | ||||||
-Cardiovascular disease (n, (%))* | 0 | 14 (51%) | 3 (33%) | 2 (18%) | 2 (20%) | |
-Auto-immune disease (n, (%))# | 0 | 1 (3%) | 1 (11%) | 0 (0%) | 0 (0%) | |
PFT, percentage predicted (95% CI) | ||||||
-TLCO | 47 (42–53) | 86 (76–95) | 33 (27–39) | 34 (27–40) | ||
-FVC | 77 (72–83) | 108 (95–121) | 53 (45–60) | 52 (44–60) | ||
-FEV1/FVC | 69 (63–73) | |||||
COPD (n) (stage) | 0 | 3 (all GOLD1) | 0 | 0 | ||
Smoking, n (%) | ||||||
-never | 5 (19%) | 2 (22%) | 2 (18%) | 2 (20%) | ||
-former | 22 (81%) | 7 (78%) | 9 (82%) | 8 (80%) | ||
-current | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Medication | ||||||
-prednisone use: (n, (%)) | 8 (30%) | 0 (0%) | 4 (36%) | 3 (30%) | ||
dose (mg/day) | ||||||
> 10 mg/d | 0 (0%) | 1 (9%) | 0 (0%) | |||
</= 10 mg/d | 8 (30%) | 3 (27%) | 3 (30%) | |||
pa Other immunosuppressive (n, (%)) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
PO Please Pirfenidone (n, (%)) | 0 (0%) | 2 (18%) | 2 (20%) | |||
Nintedanib (n, (%)) | 1 (3%) | 3 (27%) | 3 (30%) | |||